The Efficacy and Safety of PRC-063 in Adult ADHD Patients

This study is a randomized, phase III, multicenter, placebo-controlled, parallel-group,
forced-dose titration in which adult subjects (18 years of age or older) with ADHD will be
randomized to PRC-063 (25, 45, 70 or 100 mg) or placebo for four weeks of double-blind
evaluation of safety and efficacy. The study will have four phases: (1) screening and 1-week
washout; (2)baseline and double-blind, forced-dose titration over a 2-week period; (3)
double-blind evaluation over a 2-week period; and (4) a 14-day safety follow-up. Subjects
will be required to visit the site 6 times over a 5 week period.

Screening and Washout: Subjects will be screened to establish eligibility for study
participation. Subjects who meet eligibility requirements will undergo ADHD medication
washout, if applicable.

Inclusion Criteria:

- Male or non-pregnant, non-nursing female at least 18 years of age and meeting the
local, legal definition of adult.

- ADHD diagnosis, inattentive, hyperactive/impulsive or combined, as defined by the
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) based on
clinician assessment using multiple informants and a structured interview.

- Unsatisfied with his or her current pharmacological therapy for treatment of ADHD or
not currently receiving pharmacological therapy for ADHD. Inclusion of subjects naïve
to pharmacological therapy for ADHD is permitted.

- Female subjects must be one of the following: a. surgically sterile prior to
screening; b.

postmenopausal; c. if of childbearing potential, abstinent or willing to use a reliable
method of contraception, such as oral contraceptive, two barrier methods, a barrier method
plus a spermicidal agent.

- Female subjects of Child-Bearing Potential (FOCP) must have a negative serum β-hCG
pregnancy test at screening.

- Minimum level of intellectual functioning, as determined by an Intelligence Quotient
(IQ) score of 80 or above based on the WASI.

- Mentally and physically competent to sign an informed consent document indicating that
they understand the purpose of and procedures required for the study and are willing
to participate in the study.

- Able and willing to comply with the study procedures for the entire length of the
study, including a successful swallow test of an empty 100 mg capsule.

Exclusion Criteria:

- Having an allergy to methylphenidate or amphetamines or a history of serious adverse
reactions to methylphenidate.

- Known to be non-responsive to methylphenidate treatment. Non-response is defined as
methylphenidate use at various doses for a phase of at least four weeks at each dose
with little or no clinical benefit.

- Being diagnosed with or having a history of strokes, epilepsy, migraine headaches
(greater than 1 instance every two months), glaucoma, thyrotoxicosis, tachyarrhythmias
or severe angina pectoris or serious or unstable medical illness. Subjects with
controlled or stable asthma or diabetes will be permitted.

- Elevated blood pressure, defined as any values above 89 diastolic or 139 systolic, as
assessed at Visit 1.

- Clinically significant ECG abnormalities, as assessed at Visit 1.

- Clinically significant laboratory abnormalities, as assessed at Visit 1.

- Currently receiving guanethidine, pressor agents, MAO inhibitors, coumarin
anticoagulants, anticonvulsants (e.g. phenobarbital, phenytoin, primidone),
phenylbutazone, tricyclic antidepressants (e.g. imipramine, desipramine), selective
serotonin reuptake inhibitors (SSRIs) or herbal remedies (unless on a stable dose for
4 weeks).

- Subject has known history of symptomatic cardiovascular disease, advanced
arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm
abnormalities, coronary heart disease, transient ischemic attack or stroke or other
serious cardiac problems that may place the subject at increased vulnerability to the
sympathomimetic effects of a stimulant drug.

- Subject has a known family history of sudden cardiac death or ventricular arrhythmia.

- Subjects who are currently considered a suicide risk by the investigator.

- Having a primary diagnosis of schizophrenia, schizoaffective disorder, primary
affective disorder, schizotypal personality, major depression, bipolar disorder,
generalized anxiety, borderline personality disorder, antisocial personality or
another unstable psychiatric condition requiring treatment, as assessed by the
structured interview conducted at Visit 1.

- Having a history or suspected physiological dependence (excluding nicotine) on
narcotic analgesics or other psychoactive drugs (including barbiturates, opiates,
cocaine, cannabinoids, amphetamines and benzodiazepines).

- Excessive consumption of alcohol (consumes alcohol in quantities greater than 15
drinks per week; 1 drink is defined as 360 mL/12 oz. of beer, 120 mL/4 oz. of wine, or
30 mL/1 oz. of hard liquor), or history (within previous 6 months) of alcohol abuse.

- Currently (or within 30 days before the planned start of treatment) receiving an
investigational drug or using an experimental medical device.

- Homeless.